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Abstract  Although  metastatic  disease  indicates  diffusion  of  a  cancer  at  a  distance  from  its  site
of origin,  in  some  cases  pulmonary  and  hepatic  metastases  are  isolated  and  slowly  progressive,
making them  suitable  for  local  treatment.  Thermo-ablation  techniques  are  associated  with  low
morbidity and  reduced  collateral  parenchymal  damage;  they  therefore  play  an  important  role
in such  patients,  where  the  disease  is  slow  and  chronic,  requiring  repeated  local  treatments.
Unlike radiotherapy,  a  second  treatment  is  possible  in  the  event  of  local  failure.
© 2014  Published  by  Elsevier  Masson  SAS  on  behalf  of  the  Éditions  françaises  de  radiologie.Principle
The  current  produced  by  radiofrequency  (RF)  is  a  sinusoidal  current  of  400  to  500  KHz.
Tissues  that  are  traversed  by  this  current  undergo  ionic  agitation,  which  generates  heat
through  inter-particulate  friction  [1]. The  aim  is  to  expose  the  neoplastic  cells  to  a  tem-
perature  of  more  than  60 ◦C,  which  provokes  almost  immediate  and  irreversible  cellular
denaturation.  The  maximum  diameter  of  the  zone  of  tissue  destruction  induced  by  a  sim-
ple  needle  electrode  of  RF  is  only  1  to  1.5  cm,  which  is  not  suitable  for  the  treatment  of
hepatic  tumours.  Depending  on  the  manufacturers,  various  techniques  are  used  to  increase
this  area  of  destruction:
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a needle  containing  several  electrodes  (4—12),  which
are  deployed  after  insertion  in  the  target  tumour
(Figs.  1  and  2).  The  aim  is  to  obtain  as  many  single  small
RF  lesions  as  electrodes,  to  create  a  larger  area  by  sum-
mation.  The  size  and  shape  of  the  ﬁnal  lesion  therefore
depends,  among  others,  on  the  number  of  electrodes
used,  and  of  their  disposition  in  space;
cooling  of  the  electrodes  via  circulation  of  cold  liquid  in
the  sheath  of  the  electrode  limits  the  accumulation  of
heat  to  the  surrounding  tissue,  which  makes  it  possible
to  deliver  more  electric  energy  without  exceeding  100 ◦C
in  the  tissues  very  close  to  the  electrode  which  are  sub-
jected  to  greater  RF  energy  than  more  distant  tissues.  We
thus  increase  the  maximal  size  of  the  RF  lesion  that  one
can  induce;
igure 1. 3D conebeam-CT image of a radiofrequency treatment
sing a deployable needle, of a metastasis close to the REX recess,
uring selective portal occlusion obtained via a left trans-hepatic
pproach with a balloon catheter.
igure 2. Pulmonary metastasis of the lower right pulmonary lobe wit
can taken 10 min after radiofrequency treatment shows the tumour su
o the zone of destruction (b). The pneumothorax visible on this image 
lace as this pneumothorax will not recur after aspiration. On the CT sc
ondensation that will slowly decrease over time (c).
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bipolar  electrodes  make  the  RF  current  circulate  between
two  distinct  parts  of  the  same  needle  or  between  two  dif-
ferent  needles.  There  is  therefore  no  need  for  grounding
pads  on  the  skin,  unlike  for  all  other  monopolar  systems.
The  electrical  ﬁeld  is  conﬁned  between  the  electrodes
and  can  therefore  be  more  intense.  Finally,  the  generators
can  cope  with  several  needles,  therefore  several  poles  to
make  the  current  circulate  successively  between  differ-
ent  pairs  of  electrodes  to  cover  a  larger  surface  area  and
achieve  a greater  volume  of  destruction.  This  technique
is  therefore  often  (incorrectly)  termed  ‘‘multipolar’’,
whereas  it  is  actually  comprised  of  several  successive
bipolar  applications.  These  make  it  possible  to  increase
the  size  of  the  RF  destruction  zones.
ndications
hether  in  the  lung  or  liver,  the  majority  of  surgeons  limit
reatment  to  tumours  under  5 cm  in  diameter,  given  that
he  ideal  indication  is  for  tumours  under  3  cm,  as  the  failure
ate  is  higher  above  this  [2—4].  The  treatment  of  tumours
hat  are  larger  than  those  that  can  be  destroyed  with  a
ingle  dose  of  RF  require  overlapping  impacts,  which  takes
ime  and  is  always  less  effective  than  a  single  treatment.  To
nderstand  this  signiﬁcant  reduction  in  efﬁcacy  for  a  seem-
ngly  moderate  increase  in  tumour  size,  it  is  important  to
nderstand  that  a  5  cm  diameter  tumour  is  approximately
wice  as  voluminous  as  a  4  cm  tumour,  and  likewise  for  a
 cm  tumour  compared  with  a  3  cm  tumour.  Furthermore,
lthough  a  RF  system  is  capable  of  covering  a  sphere  of  tissue
estruction  of  4  cm  in  diameter  in  one  impact,  6  RF  impacts
re  required  to  cover  a sphere  of  5  cm.
The  ideal  localisation  is  at  a  distance  from  the  hepatic
apsule  or  pleura,  and  at  a  distance  from  the  hiluses.hin which a radiofrequency needle has been deployed (a). The CT
rrounded by a zone of alveolar condensation, which corresponds
has been punctured and will be aspirated. No drain will be left in
an obtained 2 months after the radiofrequency, there is a zone of
ontact  with  a  large  vessel  has  been  reported  as  a  predic-
ive  factor  for  the  failure  of  radiofrequency  treatment  of
epatic  and  pulmonary  metastases  [2—4].  This  is  due  to  the
ooling  by  convection  that  is  exerted  close  to  the  vessels.
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The  means  of  guidance  varies  as  a  function  of  the  organs
and  of  the  visibility  of  the  target  tumour.  For  the  lung,
treatment  is  always  percutaneous  and  guided  by  CT  scan
(Fig.  2).  For  the  liver,  RF  can  be  used  percutaneously  or  peri-
operatively  (laparotomy  or  laparoscopy)  under  ultrasound
guidance.  CT  scans  are  usually  reserved  for  cases  that  are
not  accessible  with  ultrasound.  If  RF  needs  to  be  used  in  an
isolated  manner,  then,  the  percutaneous  route  is  preferable
since  it  is  usually  less  invasive.  Laparoscopy  or  laparotomy
is  only  proposed  when  the  percutaneous  route  is  not  avail-
able  or  when  the  peritoneal  area  or  lymph  nodes  need  to  be
‘‘checked’’.
Result
Hepatic metastases
In  a  recent  literary  review,  the  rate  of  complete  ablation  for
hepatic  radiofrequency  varies  between  58%  and  95%;  in  the
majority  of  publications  [5],  the  success  rate  was  related  to
the  size  of  the  tumour,  as  described  above.  For  Elias  et  al.
[3],  in  the  liver,  this  failure  rate  increases  from  3%,  when
the  tumour  is  not  in  contact  with  vessels,  to  23%  when  it  is,
and  for  Lu  et  al.  from  12%  to  53%  [6].
We  recently  demonstrated  that  the  occlusion  of  vessels
in  contact  with  the  tumour  using  a  balloon  results  in  success
rates  for  radiofrequency  that  are  equivalent  for  tumours
that  are  in  contact  or  at  a  distance  from  vessels  with  89%
and  91%  success,  respectively;  this  applies  to  tumours  that
are  under  35  mm  [7]  (Fig.  1).
In  terms  of  local  efﬁcacy,  the  comparison  between
radiofrequency  and  metastasectomy  performed  by  Elias
et  al.  shows  a  similar  failure  rate,  6%  for  radiofrequency  and
7.3%  for  metastasectomy  [3].  Due  to  the  lack  of  randomised
studies,  studies  that  compare  radiofrequency  and  surgery
comprise  numerous  biases  by  often  including  very  differ-
ent  patients.  In  many  studies,  radiofrequency  is  reserved
for  non-surgical  patients  and  sometimes  even  for  patients
who  have  tumours  in  contact  with  vessels  and  vascular  struc-
tures.  They  are  the  worst  indications  for  radiofrequency
due  to  the  dispersion  of  heat  by  convection  engendered
by  the  vessels.  Berber  et  al.’s  study,  published  in  2008,
compared  extremely  different  groups  with  more  extra-
hepatic  diseases  in  the  radiofrequency  group  and  a  more
altered  WHO  state  [8].  If  one  compares  surgical  resection
and  radiofrequency  in  patients  who  do  not  have  extrahep-
atic  disease,  there  is  still  a  signiﬁcant  difference,  with  a
median  survival  of  59  months  for  surgery  and  40  months  for
radiofrequency,  but  if  one  compares  patients  with  equiv-
alent  ASA  stages,  then  radiofrequency  is  equivalent  to
surgery.
It  is  difﬁcult  to  evaluate  the  results  of  radiofrequency
in  terms  of  survival  as  this  technique  is  proposed  in  very
different  situations  in  patients  with  hepatic  colorectal
metastases.  Indeed,  this  treatment  is  proposed  at  different
stages  of  the  disease,  sometimes  as  a  last  resort  treatment
for  progressive  disease  after  chemotherapy  or  sometimes
very  early  in  the  disease  before  chemotherapy.  To  illus-
trate  this  difﬁculty,  Machi  et  al.  report  a  median  survival  of
48  months  in  patients  that  had  not  received  chemotherapy
and  a  median  of  22  months  in  those  who  had  [9].
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Experience  in  hepatic  surgery  shows  that  the  prognosis
or  local  treatment  in  patients  who  are  progressive  under
hemotherapy  is  not  as  good  as  that  of  patients  who  respond
o  treatment  or  are  stabilised  by  the  treatment  [10]. Ideally,
t  would  be  better  to  treat  hepatic  metastases  that  have
esponded  or  have  been  stabilised  by  chemotherapy.
Gillams  et  al.  report  that  patients,  with  fewer  than  5
umours  of  under  5  cm,  have  a  survival  rate  of  30%  at  5  years,
hilst  survival  is  under  5%  for  more  voluminous  or  numerous
umours  [11].  For  patients  with  a  single  hepatic  metastasis
f  under  4  cm,  the  survival  rates  at  1,  3,  and  5  years  are  97%,
4%,  and  40%,  respectively  with  a  median  survival  time  of
0  months  [12].  The  latter  results  are  quite  similar  to  those
eported  in  the  surgical  literature.  These  are  the  best  results
ver  published  for  hepatic  radiofrequency  treatment,  but
he  population  is  extremely  selective  with  a  single  tumour
f  less  than  4 cm  (mean  =  2.3  cm)  and  without  extrahepatic
isease.
A  novel  approach  explores  the  use  of  palliative  radiofre-
uency  for  reduction  in  tumour  size.  This  randomised  Dutch
tudy  compares  chemotherapy  alone  versus  radiofrequency
nd  chemotherapy  in  152  patients,  who  had  up  to  10  hepatic
etastases  of  less  than  4  cm  [13].  Survival  without  progres-
ion  is  signiﬁcantly  different  between  the  two  groups  with
0  months  in  the  chemotherapy  alone  group  and  16.8  months
n  the  radiofrequency  plus  chemotherapy  groups.  There  was
o  difference  in  overall  survival  at  30  months,  but  the  curves
eem  to  separate  late  and  the  follow-up  of  these  patients
ill  be  continued  before  publication  of  the  study.
ulmonary metastases
he  rate  of  sterilisation  of  pulmonary  tumours  using
adiofrequency  clearly  also  depends  on  the  size  of  the
umours  treated,  but  overall  the  majority  of  current  pub-
ications  agree  on  a  success  rate  of  80  to  90%  for  metastases
f  less  2  cm  [2].
In  the  lung,  contact  with  a  vessel  larger  than  3  mm
ncreases  the  failure  rate  from  23%  to  58%  in  the  lung  for
illams  et  al.  and  from  22%  to  35%  for  Iraki  et  al.  [4,14].
In  terms  of  survival,  4  series  published  in  2006/2007
eported  comparable  survival  rates  ranging  from  84%  to  90%
t  one  year,  and  from  62%  to  78%  at  2  years  [2,15—17].  These
gures  are  close  to  historical  surgical  series,  but  there  again,
he  populations  are  extremely  different,  and  the  surgical
eries  are  often  old  and  did  not  beneﬁt  from  recent  medical
dvances  in  the  management  of  cancer.
ollow-up imaging
epatic metastases
he  aim  of  treatment  via  direct  puncture  is  to  destroy  the
umour,  but  also  a  ring  of  healthy  tissue  to  obtain  ‘‘safety
argins’’  or  ‘‘ablation  margins’’.  These  destroyed  tissues
ill  obviously  stay  in  place  and  form  a  ‘‘scar’’.  This  scar  is
herefore  initially  larger  than  the  tumour  (tumour  +  safety
argins)  and  only  gets  smaller  late  on.  It  is  therefore  impos-
ible  to  use  the  usual  WHO  criteria  for  the  evaluation  of
umour  response  based  on  the  reduction  in  size  of  the
umour.  The  scar  left  behind  after  treatment  is  composed
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f  necrotic  tissue,  ﬁbrosis,  inﬂammatory  tissue,  granulation
issue,  and  viable  tumour  if  the  treatment  was  incomplete.
he  aim  of  follow-up  imaging  is  to  identify  the  presence
f  this  viable  tumour  within  the  scar.  CT  scan  and  MRI
re  the  most  commonly  used  techniques  for  this  follow-up.
hey  enable  rapidly  repeatable  acquisitions  over  time  after
njection  of  contrast  medium,  to  look  for  zones  with  early
paciﬁcation,  corresponding  in  most  cases  to  the  tumour
18].  However,  iconographic  follow-up  should  not  be  per-
ormed  too  early,  at  the  risk  of  incorrectly  interpreting  the
ichly  vascularised  granulation  tissue  resulting  from  treat-
ent  as  tumour  residue,  this  develops  principally  in  the
eriphery  of  the  destroyed  zone,  and  persists  for  at  least
 to  6  weeks.  This  is  why  it  is  usually  recommended  to  start
ollow-up  imaging  around  8  weeks  after  treatment,  unless  a
omplication  is  suspected  or  the  treatment  is  considered  as
learly  incomplete  by  the  surgeon  during  the  RF  procedure.
he  scar  begins  to  shrink  a  few  moths  after  treatment,  but
his  post-RF  scar  usually  persists  for  many  years.  Two  partic-
lar  post-therapeutic  aspects  should  be  recognised  and  not
onfused  with  contrast  uptake  by  residual  tumour  tissue.
he  ﬁrst  is  the  presence  of  a  ﬁne  ring  (<  1  mm)  of  contrast
ptake  (visible  on  CT  and  MRI)  surrounding  the  entire  cir-
umference  of  the  necrotic  zone.  This  contrast  uptake  is
rogressive,  absent  in  the  arterial  phase  and  maximal  in
he  late  phase.  It  is  present  in  32%  of  cases  in  our  series
nd  on  histology,  it  corresponds  to  non-neoplastic  inﬂam-
atory  granulation  tissue  in  the  hepatic  parenchyma  next
o  the  coagulation  necrosis  [18].  The  second  is  the  presence
f  triangular  areas  of  contrast  uptake  with  clear  contours,
isible  in  the  arterial  phase,  at  the  periphery  of  the  post-
F  necrotic  zones.  These  correspond  to  perfusion  anomalies
nduced  by  the  treatment.  They  are  present  in  12%  of  cases
n  our  series.
ulmonary metastases
he  rate  of  complete  ablation  actually  depends  on  the  vol-
me  of  ablation  relative  to  the  volume  of  the  tumour;  the
argins  of  ablation  are  therefore  a  signiﬁcant  predictive
actor  [2,14].  We  have  described,  for  pulmonary  metastases,
hat  a  ground  glass  opacity  that  shows  an  ablation  zone  that
s  four  times  as  large  as  the  tumour  is  a  predictive  factor  for
uccess  with  96%  destruction,  compared  with  80%  destruc-
ion  when  this  objective  is  not  attained.  Similarly,  it  has
een  reported  that  the  margins  of  ablation  were  absent  in
5%  of  cases  of  tumours  that  relapsed;  in  the  same  study,
n  ROC  analysis  constructed  from  relapse  as  a  function  of
inimal  ground  glass  opacity  after  ablation  conﬁrms  that  if
 4.5  cm  margin  of  ablation  is  obtained  all  the  way  around
he  tumour,  the  success  rate  for  destruction  is  100%.
It  is  therefore  very  important  to  make  the  zones  of  abla-
ion  larger  than  the  size  of  the  tumours  to  increase  the
uccess  rate  (Fig.  2).
The  PET  scanner  is  extremely  interesting  for  monitoring
ulmonary  metastases  treated  with  radiofrequency  since  it
s  capable  of  detecting  a  local  relapse  on  the  treatment  site
ith  more  sensitivity  that  conventional  CT  scan,  and  above
ll,  it  is  capable  of  detecting  local  recurrences  earlier  [19].
ndeed,  we  demonstrated  that  PET,  at  3  months,  has  a  very
igh  sensitivity  whilst  it  was  unusual  to  discover  incomplete
reatment  between  6  months  and  1  year  after  treatment.
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he  advantage  of  PET  in  pre-treatment  is  to  alter  the  thera-
eutic  attitude  in  30%  of  cases  with  either  an  association  of
ther  RF  sites,  or  association  of  surgical  treatment,  or  aban-
on  of  local  treatment  as  the  disease  is  diffuse.  This  beneﬁt
as  not  yet  been  clearly  demonstrated  for  the  evaluation  of
epatic  metastases.
olerance
adiofrequency  was  initially  proposed  for  cases  with  a  con-
raindication  for  surgery:  it  was  only  used  in  patients  that
ere  inoperable.  This  is  true  in  the  liver,  notably  for  hepato-
ellular  carcinoma,  but  also  in  the  lung  for  primary  bronchial
ancers  combined  with  advanced  COPD  or  for  metastases  in
atients  who  have  already  undergone  several  surgeries  or
ho  have  signiﬁcant  co-morbidities.
RF  preserves  the  healthy  parenchyma  and  thus,  the
unction  of  the  organ  since  the  volumes  of  parenchymal
estruction  are  extremely  low.  This  is  demonstrated  by  an
bsence  of  alteration  in  respiratory  function  after  treat-
ent,  with  notably  preservation  of  the  FEV1  in  several
tudies  [2,20].  As  such,  the  lower  limit  of  the  FEV1  and
espiratory  function  for  patients  in  whom  this  technique
an  be  proposed  has  not  been  deﬁned.  A  recent  publica-
ion  shows  that  this  treatment  can  be  used  with  relative
afety  in  patients  with  a  single  lung,  although  it  is  important
o  remember  that  in  this  context,  this  treatment  presents
bvious  life-threatening  risks,  which  have  been  elsewhere
21].
Pneumothorax  occurs  after  50%  of  pulmonary  punctures
ia  radiofrequency.  It  is  usually  drained  in  between  8  and
5%  of  cases,  and  constitutes  more  of  an  expected  secondary
ffect  of  radiofrequency  than  an  actual  complication.  True
omplications  include  pulmonary  haemorrhage  and  infec-
ion,  occurring  in  fewer  than  1  and  3%  of  treatments,
espectively.  Infection  is  most  common  in  patients  with  pri-
ary  bronchial  cancer  as  the  latter  often  develops  on  an
ltered  pulmonary  parenchyma,  which  is  more  susceptible
o  infection.
A  legitimate  concern  is  the  production  of  gas  during  the
oiling  of  pulmonary  tumours,  which  could  be  evacuated  via
he  pulmonary  veins.  During  pulmonary  radiofrequency,  gas
ubbles  have  been  detected  in  the  carotid  artery,  but  until
ow,  only  one  neurological  complication  has  been  reported
ollowing  radiofrequency  out  of  several  thousand  published
ases  [22].  More  difﬁcult  to  avoid,  although  extremely  rare,
s  gas  embolism  caused  by  inspired  air  in  the  lung:  two  sep-
rate  cases  have  been  reported  in  the  literature  [23,24].  It
hould  be  noted  that  these  cases  occurred  even  before  the
articipation  of  radiofrequency  and  that  they  were  caused
y  needle  placement  and  tearing  of  the  parenchyma.  In  one
ase,  the  patient  had  undergone  extensive  radiotherapy  and
he  needle  was  difﬁcult  to  insert  due  to  the  extremely  fri-
ble  and  ﬁbrous  parenchyma.onclusion
adiofrequency  is  a  promising  treatment  that  originally
rose  out  of  the  contraindications  for  surgery,  and  should  in
requ
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the  future  replace  surgery  in  certain  indications  with  small
tumours.
As  a  curative  treatment  of  small  tumours,  it  will  be  in
competition  with  conformational  radiotherapy  techniques
(tomotherapy  and  gamma  knife).  Are  these  techniques  com-
petitors  or  could  they  be  proposed  as  a  combined  treatment
to  improve  results?  Ideally,  randomised  trials  are  needed
in  the  treatment  of  small  pulmonary  and  hepatic  metas-
tases  for  comparison  with  surgery.  In  practice,  such  trials  are
extremely  difﬁcult  to  implement,  ﬁrstly  due  to  patient  con-
sent  and  secondly  due  to  the  fact  that  ‘‘good  candidates’’
for  surgery  are  usually  poor  candidates  for  radiofrequency
and  vice  versa.
A recent  study  into  cytoreductive  radiofrequency  reveals
a  new  ﬁeld  of  investigation  for  radiofrequency  that  could  be
used  for  palliative  therapy.
Finally,  the  treatment  of  tumours  over  3  cm  will  certainly
involve  other  techniques,  such  as  microwaves,  which  are
under  development.
TAKE-HOME  MESSAGES
• The  ideal  indications  for  pulmonary  and  hepatic
radiofrequency  are  tumours  under  3  cm.
• The  ideal  localisation  of  the  tumour  is  at  a  distance
from  any  large  vessels,  which  multiply  the  failure
rate  four-fold  due  to  their  cooling  effect.
• Comparison  between  hepatic  radiofrequency  and
metastasectomy  shows  a  failure  rate  of  6%  and  7.3%,
respectively  for  tumours  of  25  mm  or  under.
• Radiofrequency  of  a  single  hepatic  metastasis  of
under  4  cm  enables  survival  at  1,  3,  and  5  years  of
97%,  84%,  and  40%,  respectively.
• CT  scan  and  MRI  are  the  most  commonly
used  techniques  for  the  follow-up  of  hepatic
radiofrequencies.  They  are  used  to  look  for  zones
of  tumour  persistence,  which  show  early  increased
uptake.
• On  these  examinations,  a  ﬁne  ring  (<  1  mm)
of  contrast  uptake  surrounding  the  entire
circumference  of  the  necrotic  zone  and  the
presence  of  triangular  areas  of  contrast  uptake
with  sharp  borders,  visible  in  the  arterial  phase,
are  not  a  sign  of  recurrence  but  of  inﬂammation  or
arterio-portal  ﬁstula.
• A  ground  glass  opacity  with  an  area  that  is  four  times
greater  than  the  targeted  pulmonary  tumour,  is  a
predictive  factor  for  success.
• A  PET  scan  is  the  best  method  for  monitoring
pulmonary  metastases  that  have  been  treated  with
radiofrequency.
Clinical case
Questions1)  The  ‘‘Heat  sink  effect’’:
1  is  thermal  loss  by  convection.
2  is  thermal  loss  by  conduction.ency  687
3  is  responsible  for  reducing  the  efﬁcacy  of  radiofre-
quency  close  to  vessels.
4  promotes  complete  ablation.
)  Pulmonary  radiofrequency:
1  is  the  treatment  of  choice  for  pulmonary  metastases
of  under  2  cm.
2  it  can  be  proposed  for  the  treatment  of  pulmonary
metastases  under  4  cm.
3  is  more  effective  locally  than  stereotactic  radiothe-
rapy.
4  destroys  around  99%  of  tumours  under  2  cm.
)  Pulmonary  radiofrequency:
1  is  guided  under  ﬂuoroscopy.
2  is  guided  by  CT  scan.
3  induces  around  40%  pneumothorax,  and  10%  pneu-
mothorax  to  be  drained.
4  involves  the  imperative  use  of  deployable  needles.
)  Hepatic  radiofrequency:
1 is  guided  under  ultrasound  only.
2  is  more  effective  than  alcoholisation  for  the  treatment
of  metastases.
3  requires  coagulation  of  the  trajectory  of  the  needle  to
reduce  tumour  seeding.
4  involves  the  imperative  use  of  deployable  needles.
)  Pulmonary  radiofrequency:
1  is  more  effective  than  stereotactic  radiotherapy.
2  destroys  around  80%  of  metastases  under  2  cm.
3  prolongs  the  survival  of  treated  patients.
4  induces  around  70%  survival  at  3  years
)  Follow-up  imaging  after  percutaneous  ablation  via
hepatic  radiofrequency:
1  is  not  necessary  as  the  tumour  has  been  destroyed.
2  initially  reveals  a  treatment  zone  that  is  larger  than
the  tumour.
3 does  not  need  to  be  continued  beyond  9  months.
4  can  be  performed  by  CT  scan,  but  MRI  enables  earlier
detection  of  possible  incomplete  treatments.
nswers
)  Correct:  1,  3.
)  Correct:  2,  4.
)  Correct:  2,  3.
)  Correct:  2,  3.
)  Correct:  2,  4.
)  Correct:  2,  4.
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